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BCR-ABL1-positive (i.e., Philadelphia-positive) acute myeloid leukemia (AML) is a very rare entity, which represents less than 1% of de novo AML, and has been included in the 2016-revised World Health Organization (WHO) classification as a provisional entity. 1 The clinical relevance of harboring a targetable fusion such as BCR-ABL1 is felt to warrant a provisional disease category. 1, 2 From the clinical standpoint, distinction between bona fide AML with BCR-ABL1 fusion gene and an initial myeloid blast phase of CML (myeloid BC-CML) presenting d'embl ee may be difficult without adequate clinical information, in the absence of a preceding diagnosed chronic phase of CML. Absence of marked splenomegaly and peripheral blood and/or bone marrow basophilia, presence of myelodysplasia-related changes, identification of normal, non t (9;22) metaphases in the initial cytogenetic study, or detection of other concomitant recurrent AML genetic lesions such as core-binding factor rearrangements or NPM1 mutations are clinical hints that might help to establish a diagnosis of BCR-ABL1-positive AML. 2, 3 Recent genomic data support the biological uniqueness of BCR-ABL1-positive AML, which shares with lymphoid variants of BCR-ABL1-positive leukemias (i.e., BCR-ABL1 acute lymphoblastic leukemia and lymphoid blast crisis of CML) deletions of the antigen receptor genes IGH and TCR, IKZF1, and CDNK1A/B, never observed in myeloid BC-CML, showed distinctive gains in several genomic regions, and do not present with characteristic mutations of ABL1 observed in myeloid BC-CML. 3, 4 The most common BCR-ABL transcripts (p190 and p210) are nearly equally distributed. 5, 6 Historically, the prognosis of BCR-ABL1-positive AML has been considered poor, with marked chemoresistance; accordingly, the 2017
European Leukemianet risk stratification allocated AML with t(9;22) (q34.1;q11.2); BCR-ABL1 to the adverse risk category. 7 Although there is no consensus about the standard of treatment for the patients with BCR-ABL1-positive AML, the addition of tyrosine-kinase inhibitors (TKI) with activity against ABL to AML-type therapy has been adopted as a common practice, similarly to BCR-ABL-positive B-precursor ALL. 5, 6 Moreover, most of the authors agree that there is an indication for allogeneic stem cell transplantation in first complete remission in eligible patients. [8] [9] [10] [11] [12] [13] [14] Nonetheless, there is a complete lack of evidence regarding many different aspects of treatment, such as the optimal TKI to be used in this context, best AML type chemotherapy to be combined with, or the role of maintenance therapy post-transplant to prevent relapse. [8] [9] [10] [11] 13 Case reports and small series in recent years showed favorable results after allogeneic SCT, as exemplified in the largest group of the patients with BCR-ABL1-positive AML who underwent alloSCT reported so far, with a remarkable 2-year overall survival of 68% with an additional specific questionnaire to obtain more detailed information of the clinical characteristics and outcome, with a special focus on TKI use pre and post-SCT, including specific agent and treatment duration. Queries were clarified by phone or written communication.
| Statistical methods
The starting point for time-to-event analysis was date of transplanta- patients (34%) received a TKI either as maintenance (n 5 9) or treatment for overt relapse (n 5 9). Among patients who received a TKI for an overt relapse, 5 remain alive at last follow-up with a sustained response, ranging from 40 to 140 months after SCT. Donor lymphocyte infusion (DLI) was given in 7 patients that relapsed post SCT (Supporting Information Table S4 ).
| Transplantation outcome
Nonrelapse mortality (NRM), relapse incidence (RI), leukemia-free sur- 
| D I SCUSSION
In the current study, we report the largest cohort of patients with BCR-ABL1-positive AML who received an alloSCT with a prolonged followup, considering that this is an extraordinary rare entity. Despite previous reports in the literature indicating a very poor prognosis, with a median overall survival between 9-24 months, outcome of patients herein described was relatively favorable, especially in first CR1, with a OS of almost 60% at 5 years, and a relapse incidence of 36%, confirming the outcome of other studies performed in in recent years. 3, 10, 15 .
These results reflect with a high probability the benefit provided by the addition of TKI to standard chemotherapy, used before SCT in the majority of the herein reported patients (70%) months following transplantation and a maximum interval of 17 months following the procedure, suggesting the need to address prophylactic or preemptive interventions to prevent relapses in the very immediate post-transplant period.
Age (<50 years) and MRD status at transplant were the only prognostic factors identified in our study. Previous publications, although predominantly case reports and small series of patients largely confirm the significance of lower age and CR on a better outcome after allogeneic stem cell transplantation. 5, [9] [10] [11] 13, 15 These findings highlight the importance to achieve a deeper control of the disease before the transplant, and monitor molecularly defined MRD as the therapeutic objective in these patients, as proposed in BCR-ABL1 B-ALL and CML. during induction and consolidation phase), and the outcome after allogeneic SCT is better in patients who achieve MRD-negativity before the transplantation. [21] [22] [23] At the present moment, a treatment algorithm including an initial cytoreductive phase based on the combination of AML-type intensive chemotherapy with a adequate TKI aimed to achieve a deep molecular response followed by SCT is the best current option in BCR-ABL1-positive AML, considering, on one hand, the poor results obtained in the pre-TKI era, and on the other hand, the higher biological heterogeneity and less addiction to BCR-ABL1 compared to CML chronic phase. [12] [13] [14] 24, 25 Prognostic impact of age may be related to intrinsically biological characteristics of AML in elderly patients, such as the higher incidence of high-risk cytogenetic lesions such as aneuploidies of chromosomes 5 and 7, or gene mutations in genes such as RUNX1, ASXL1, splicing factors or other chromatin remodeling genes, associated to a poor response to standard chemotherapy. 7, 26 This study can not provide any evidence on the role of conditioning intensity in this setting, where almost every patient < 50 years received MAC (29/30) and nearly equal number of patients 50 years of age received RICT (n 5 15) and MAC (n 5 12).
Undoubtedly, our study suffers from several limitations due to its retrospective registry-based nature, although a specific questionnaire was designed to collect essential information such as details on TKI therapy. Additionally, sample size is small for further prognostic analysis on transplant features, a circumstance inherent to the low frequency of BCR-ABL1-positive AML. Finally, we should consider the assumption of a selection bias, due to referral to SCT to younger patients and with less comorbidity showing a reasonably better pretransplant response.
With all these limitations we may conclude that outcome of patients with BCR-ABL1-positive AML receiving allogeneic SCT in CR is recent years is encouraging, especially in younger patients, reflecting the very possible synergy between TKIs and graft-versus leukemia effect, although many uncertain issues on the optimal management of these patients still remain. 
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